Proteasome inhibition causes epithelial–mesenchymal transition upon TM4SF5 expression

Transmembrane 4 L six family member 5 (TM4SF5) is highly expressed in hepatocarcinoma and causes epithelial–mesenchymal transition (EMT) of hepatocytes. We found that TM4SF5‐expressing cells showed lower mRNA levels but maintained normal protein levels in certain gene cases, indicating that TM4SF5 mediates stabilization of proteins. In this study, we explored whether regulation of proteasome activity and TM4SF5 expression led to EMT. We observed that TM4SF5 expression caused inhibition of proteasome activity and proteasome subunit expression, causing morphological changes and loss of cell–cell contacts. shRNA against TM4SF5 recovered proteasome expression, with leading to blockade of proteasome inactivation and EMT. Altogether, TM4SF5 expression appeared to cause loss of cell–cell adhesions via proteasome suppression and thereby proteasome inhibition, leading to repression of cell–cell adhesion molecules, such as E‐cadherin. J. Cell. Biochem. 112: 782–792, 2011. © 2010 Wiley‐Liss, Inc.

[1]  M. Seiki,et al.  Cell Adhesion in Cancer , 2012, International journal of cell biology.

[2]  K. Lindsten,et al.  Stressing the ubiquitin-proteasome system. , 2010, Cardiovascular research.

[3]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[4]  D. Spandidos,et al.  Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction , 2009, Oncogene.

[5]  M. Nieto,et al.  Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. , 2009, The Journal of clinical investigation.

[6]  Raghu Kalluri,et al.  EMT: when epithelial cells decide to become mesenchymal-like cells. , 2009, The Journal of clinical investigation.

[7]  K. Miyazono,et al.  Regulation of the stability of cell surface E-cadherin by the proteasome. , 2009, Biochemical and biophysical research communications.

[8]  Jung Weon Lee,et al.  Blockade of four‐transmembrane L6 family member 5 (TM4SF5)‐mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative , 2009, Hepatology.

[9]  Samy Lamouille,et al.  TGF-β-induced epithelial to mesenchymal transition , 2009, Cell Research.

[10]  Keiji Tanaka,et al.  Molecular mechanisms of proteasome assembly , 2009, Nature Reviews Molecular Cell Biology.

[11]  M. Muratani,et al.  Modulation of RNA polymerase II subunit composition by ubiquitylation , 2008, Proceedings of the National Academy of Sciences.

[12]  Jung Weon Lee,et al.  Regulation of TM4SF5-mediated tumorigenesis through induction of cell detachment and death by tiarellic acid. , 2008, Biochimica et biophysica acta.

[13]  Robert A. Weinberg,et al.  Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. , 2008, Developmental cell.

[14]  A. Ben-Ze'ev,et al.  Epithelial-mesenchymal transition and the invasive potential of tumors. , 2008, Trends in molecular medicine.

[15]  Semi Kim,et al.  Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma. , 2008, The Journal of clinical investigation.

[16]  R. Muschel,et al.  Tetraspanin in oncogenic epithelial-mesenchymal transition. , 2008, The Journal of clinical investigation.

[17]  R. Kalluri,et al.  Mechanisms of metastasis: Epithelial‐to‐mesenchymal transition and contribution of tumor microenvironment , 2007, Journal of cellular biochemistry.

[18]  B. Rubino,et al.  The role of epithelial-mesenchymal transition in cancer pathology. , 2007, Pathology.

[19]  N. Wahab,et al.  A Critical Look at Growth Factors and Epithelial-to-Mesenchymal Transition in the Adult Kidney , 2006, Nephron Experimental Nephrology.

[20]  B. Hausott,et al.  Constitutively expressed catalytic proteasomal subunits are up‐regulated during neuronal differentiation and required for axon initiation, elongation and maintenance , 2006, Journal of neurochemistry.

[21]  J. Thiery,et al.  Complex networks orchestrate epithelial–mesenchymal transitions , 2006, Nature Reviews Molecular Cell Biology.

[22]  P. Richardson,et al.  Proteasome inhibition as a novel therapeutic target in human cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Hung,et al.  Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial–mesenchymal transition , 2004, Nature Cell Biology.

[24]  J. Adams.  The development of proteasome inhibitors as anticancer drugs. , 2004, Cancer cell.

[25]  Fan Zhang,et al.  On and off: proteasome and TGF-β signaling , 2003 .

[26]  J. Adams,et al.  The proteasome: structure, function, and role in the cell. , 2003, Cancer treatment reviews.

[27]  J. Thiery.  Cell adhesion in cancer , 2003 .

[28]  M. Muratani,et al.  How the ubiquitin–proteasome system controls transcription , 2003, Nature Reviews Molecular Cell Biology.

[29]  Birgit Luber,et al.  Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. , 2002, The American journal of pathology.

[30]  T. Kodadek,et al.  The 19S regulatory particle of the proteasome is required for efficient transcription elongation by RNA polymerase II. , 2001, Molecular cell.

[31]  B. Boyer,et al.  Induction and regulation of epithelial-mesenchymal transitions. , 2000, Biochemical pharmacology.

[32]  T. Tsukamoto,et al.  Cell-Cell Dissociation upon Epithelial Cell Scattering Requires a Step Mediated by the Proteasome* , 1999, The Journal of Biological Chemistry.

[33]  C. Pickart,et al.  Mechanisms underlying ubiquitination. , 2001, Annual review of biochemistry.